Venous thrombosis and tissue plasminogen activator release deficiency: a family study.

Endovascular thrombolysis for pediatric cerebral sinus venous thrombosis with tissue plasminogen activator and abciximab.

Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis.

Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy.

Homocystinuria with Cerebral Venous Sinus Thrombosis: Excellent Recovery with Intravenous Recombinant Tissue Plasminogen Activator.

Free protein S deficiency in a family with venous thrombosis.

Cell-specific regulation of plasminogen activator inhibitor 1 and tissue type plasminogen activator release by human kidney mesangial cells.

Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis--influence of prophylaxis with a low molecular weight heparin. The Venous Thrombosis Group.

Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.

Human tissue-type plasminogen activator.

Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.

[Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator].

Aortic thrombosis successfully treated with local recombinant tissue plasminogen activator in a newborn.

A neonatal thrombosis patient treated successfully with recombinant tissue plasminogen activator.

Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator.

The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.

[Plasminogen activator inhibitor 1--a new thrombosis risk marker].

Tissue Plasminogen Activator: Side Effects and Signaling.

Recombinant Tissue Plasminogen Activator in the Treatment of Neonates with Intracardiac and Great Vessels Thrombosis.

Postoperative deep vein thrombosis and plasma levels of tissue plasminogen activator inhibitor.

Low-dose tissue plasminogen activator and standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations: a review.

Studies on the release of plasminogen activator.

Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.

u-PA chimera) in a combined arterial and venous thrombosis model in the dog.

Circadian fluctuations of tissue plasminogen activator antigen and plasminogen activator inhibitor-1 antigens in vasospastic angina.

Suggest Documents

Endovascular thrombolysis for pediatric cerebral sinus venous thrombosis with tissue plasminogen activator and abciximab.

Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis.

Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy.

Homocystinuria with Cerebral Venous Sinus Thrombosis: Excellent Recovery with Intravenous Recombinant Tissue Plasminogen Activator.

Free protein S deficiency in a family with venous thrombosis.

Cell-specific regulation of plasminogen activator inhibitor 1 and tissue type plasminogen activator release by human kidney mesangial cells.

Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis--influence of prophylaxis with a low molecular weight heparin. The Venous Thrombosis Group.

Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.

Human tissue-type plasminogen activator.

Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.

[Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator].

Aortic thrombosis successfully treated with local recombinant tissue plasminogen activator in a newborn.

A neonatal thrombosis patient treated successfully with recombinant tissue plasminogen activator.

Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator.

The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.

[Plasminogen activator inhibitor 1--a new thrombosis risk marker].

Tissue Plasminogen Activator: Side Effects and Signaling.

Recombinant Tissue Plasminogen Activator in the Treatment of Neonates with Intracardiac and Great Vessels Thrombosis.

Postoperative deep vein thrombosis and plasma levels of tissue plasminogen activator inhibitor.

Low-dose tissue plasminogen activator and standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations: a review.

Studies on the release of plasminogen activator.

Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.

u-PA chimera) in a combined arterial and venous thrombosis model in the dog.

Circadian fluctuations of tissue plasminogen activator antigen and plasminogen activator inhibitor-1 antigens in vasospastic angina.

Venous thrombosis and tissue plasminogen activator release deficiency: a family study.

Recommend Documents

Follow Us